Treatment with @mg rituximab resulted in significantly greater depletion ( lower B cell and plasmablast numbers between @ and @weeks ) paralleled by significantly better EULAR and ACR@ response rates at @weeks ( p = @ and p = @ , respectively ) and @weeks ( p = @ and p = @ , respectively ) compared with @mg .